Shahid Raza Khalid, Nasir Hassan Luk, Shakil Ahmed Mirza, Farrukh Saeed, Shoaib Nayyar Hashmi, Sajid Mushtaq, Amjad Tanvir, Waris Ali Rana


Background: Not all patients with histologically mild chronic Hepatitis C progress to cirrhosis.
Many patients being treated on the basis of raised ALT and positive PCR alone may not be
actually requiring it. Methods: All adult patients suffering from chronic Hepatitis C, qualifying
for combination interferon ribavirin therapy, under went liver biopsies. Tissue samples were sent
to Armed Forces Institute of Pathology (AFIP) Rawalpindi for histopathology. Reporting was
done according to modified Ishaq score. Results: Total number of patients was 147. Out of these,
75 (51%) were female and 72 (49%) were male. Mean age of females and males were 35.1±8.12
and 36.31±8.56 year respectively. Out of these, 19 (12.9%) were stage zero, 61 (41.5%) at stage 1,
and 31 (21.1%) at stage 2 of modified fibrotic Ishaq score. In all, 111 (75.5%) of the patients were
≤2 of modified Ishaq fibrotic score in either sex or 80 (54.4%) ≤1 of modified Ishaq fibrotic stage.
The necroinflammatory score has been divided into minimal (0–3), mild (4–8), moderate (9–13),
and severe (14–18). About the same number of our patients (74%) had minimal to mild
inflammation. Conclusion: Since the majority of the patients have fibrotic score less than 3, so it
will be cost effective to individualise their treatment on liver histpathology. Patients with low
fibrotic score and minimal to mild inflammation may not be treated, but only monitored with
serial ALT and liver biopsy every 4–5 years. Treatment may be started if there is increase in
fibrosis on surveillance biopsy. However, there is a need to conduct prospective studies in similar
group of patients to evaluate the natural course of disease in untreated patients.
Keywords: liver biopsy, chronic liver disease, HAI score, HCV

Full Text:



Luby SP, Qamruddin K, Shah AA, Omair A, Pasha O, Khan

AJ, et al. The relationship between therapeutic injections and

high prevalence of hepatitis C infection in Hafizabad,

Pakistan. Epidemiol Infect 1997;119:349–56.

Tong, MJ, El-Farra, NS, Reikes, AR, Co, RL. Clinical

outcomes after transfusion-associated hepatitis C. N Engl J

Med 1995;332:1463–6.

Takahashi, M, Yamada, G, Miyamoto, R, Doi, T, Endo, H,

Tsuji, T, et al. Natural course of chronic hepatitis C. Am J

Gastroenterol 1993;88:240–3.

Yano, M, Kumada, H, Kage, M, Ikeda, K, Shimamatsu, K,

Inoue, O, et al. The long-term pathological evolution of

chronic hepatitis C. Hepatology 1996;23:1334–40.

Kenny-Walsh, E. Clinical outcomes after hepatitis C infection

from contaminated anti-D immune globulin. N Engl J Med


Levine RA, Sanderson SO, Ploutz-Snyder R, Murray F, Kay

E, Hegarty J, et al. Assessment of fibrosis progression in

untreated Irish women with chronic hepatitis C contracted

from immunoglobulin anti-d. Clin Gastroenterol Hepatol


Davis GL, Lau JY. Factors predictive of a beneficial response to

therapy of hepatitis C. Hepatology 1997;26(suppl 1):122S–127S.

Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo

G, Bain V, et al. Randomised trial of interferon alpha2b plus

ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b

plus placebo for 48 weeks for treatment of chronic infection

with hepatitis C virus. International Hepatitis Interventional

Therapy Group (IHIT). Lancet 1998;352:1426–32.

Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ, Costeffectiveness of treatment for chronic hepatitis C infection in

an evolving patient population. JAMA 2003;290:228–37.

Khokhar N, Jadoon H A. Percutaneous liver biopsy using

spinal needle. Pak J Gastroenterol 2002;16(1):9–11.

Jadoon HA. Liver biopsy with spinal (lumber puncture)

needle-A Cheaper alternative. J Ayub Med Coll Abbottabad


Sheikh NI, Ahmed SI, Zaheer S, Fatima SA. Evaluation of

liver biopsy as a safe procedure carried out in day surgery

setting. J Rawal Med Coll 2004;8(2):69–71.

Seeff, LB. Natural history of hepatitis C. Hepatology



  • There are currently no refbacks.

Contact Number: +92-992-382571

email: [jamc] [@] []